Skip to content

Effect of Soluble Corn Fiber Supplementation for 1 Year on Bone Metabolism in Adolescents

Effect of Soluble Corn Fiber Supplementation for 1 Year on Bone Metabolism in Adolescents

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02916862
Acronym
MetA-Bone
Enrollment
177
Registered
2016-09-28
Start date
2020-02-10
Completion date
2025-04-30
Last updated
2025-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Keywords

fiber, calcium absorption, bone mass, adolescents

Brief summary

The primary aim of this proposal is to determine the effects of soluble corn fiber (SCF) supplementation for 1 year on bone metabolism in growing adolescents compared to controls. For the proposed study, a randomized double-blinded placebo controlled clinical trial will be conducted in 236 healthy adolescents aged 10-13 years, equally randomly assigned to one of four intervention groups: SCF (12 g/d), SCF + calcium (12 g/d of SCF + 600 mg/d of elemental calcium), placebo (0 g/d of SCF or of calcium), and placebo + calcium (0 g/d of SCF + 600 mg/d of elemental calcium); all administered twice a day. Bone mass will be assessed at baseline at 6 months and at 12 months and bone related biomarkers and fecal microbiome will be assessed at baseline and at 12 months.

Detailed description

The adolescent period is crucial for optimizing future bone health because bone accumulates rapidly during these years and accounts for up to half of adult peak bone mass. Calcium intake during this period is critical for adequate bone mineralization but this is the nutrient most deficient in the diets of adolescents. A strategy to maximize bone mineralization during this critical period is to increase the absorption of the calcium being consumed. This could be achieved by supplementing diets with certain non-digestible carbohydrates, such as soluble corn fiber (SCF). The primary aim of this study is to determine the effects of SCF supplementation for 1 year on bone metabolism in growing adolescents compared to controls. A randomized double-blinded placebo controlled clinical trial will be conducted in 236 healthy adolescents aged 10-13 years, equally randomly assigned to one of four intervention groups: SCF (12 g/d), SCF + calcium (12 g/d of SCF + 600 mg/d of elemental calcium), placebo (0 g/d of SCF or of calcium), and placebo + calcium (0 g/d of SCF + 600 mg/d of elemental calcium); all administered twice a day. Bone mass will be assessed at baseline at 6 months and at 12 months and bone related biomarkers and fecal microbiome will be assessed at baseline and at 12 months. The treatments will be provided in the form of flavored drinks twice per day (this was previously used in a short-term study among adolescents with excellent acceptance). Bone mass and anthropometric measurements will be assessed at baseline, at 6 months and at 12 months and bone related biomarkers and fecal microbiome will be assessed at baseline and at 12 months. Assessment visits will be conducted in the Clinical Research Center of the Stempel School of Public Health at Florida International University. We will also have short home visits at 3 and 9 months to collect unused supplements and provide more supplements. In all visits, participants will complete several questionnaires, such as general health, diet and activity questionnaire. Compliance will be evaluated at all visits and also in real time using a study mobile app. The primary outcome is change in bone mineral content (BMC) measured using Dual-energy X-ray absorptiometry (DXA) The secondary outcomes include biochemical markers reflecting vitamin D status, calcium homeostasis and bone, such as serum calcium, phosphorus, creatinine, osteocalcin, carboxy-terminal collagen crosslinks (CTX), parathyroid hormone (PTH), bone specific alkaline phosphatase, 25-(OH) vitamin D3, 1,25-(OH)2 vitamin D3, and insulin growth factor 1 (IGF-I) and urinary calcium, phosphorus, creatinine and N-telopeptide cross-links.

Interventions

DIETARY_SUPPLEMENTSoluble Corn Fiber (SCF) without Calcium

Participants will consume a supplement with 12 g/day of SCF for 12 months

COMBINATION_PRODUCTSoluble Corn Fiber (SCF) + Calcium

Participants will consume a supplement with 12 g/day of SCF + calcium carbonate (600 mg/day) for 12 months

DIETARY_SUPPLEMENTPlacebo

Participants will consume a supplement without SCF or calcium carbonate for 12 months

COMBINATION_PRODUCTPlacebo + calcium

Participants will consume a supplement without SCF + calcium carbonate (600 mg/day) for 12 months

Sponsors

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
CollaboratorNIH
Florida International University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Intervention model description

we are testing a fiber and calcium supplement so it is not a drug

Eligibility

Sex/Gender
ALL
Age
9 Years to 14 Years
Healthy volunteers
Yes

Inclusion criteria

* Body mass index between the 5th and 85th percentiles for age and sex based on the Centers for Disease Control Growth Charts.

Exclusion criteria

* Subjects with any chronic illness requiring regular medication use. * Those taking calcium supplements (\>500 mg/d) and vitamin D supplements (\>400 IU/d) on a regular basis

Design outcomes

Primary

MeasureTime frameDescription
Change in Whole Body Bone Mineral Content (BMC)12 monthsParticipants underwent a bone scan at baseline and after 12-months in the intervention using a dual energy x-ray absorptiometry (DXA)

Secondary

MeasureTime frameDescription
Change in Spine BMC12 monthsParticipants underwent a bone scan at baseline and after 12-months in the intervention using a dual energy x-ray absorptiometry (DXA)

Countries

United States

Participant flow

Recruitment details

Although 213 were recruited (signed consent form), only 177 completed the randomization visit and were randomized.

Pre-assignment details

Randomization was pre-determined using a block randomization document, which was computer generated.

Participants by arm

ArmCount
Soluble Corn Fiber (SCF) + Calcium
This group received 12 g/d of soluble corn fiber (SCF) + 600 mg/d of elemental calcium carbonate, administered twice a day Soluble Corn Fiber (SCF) + Calcium: Participants consumed a supplement with 12 g/day of SCF + calcium carbonate (600 mg/day) for 12 months
45
Soluble Corn Fiber (SCF) Without Calcium
This group received 12 g/d of soluble corn fiber (SCF) + 600 mg/d of elemental calcium carbonate, administered twice a day Soluble Corn Fiber (SCF) without Calcium: Participants consumed a supplement with 12 g/day of SCF for 12 months
43
Placebo
This group received a similar supplement without SCF or calcium, administered twice a day Placebo: Participants consumed a supplement without SCF or calcium carbonate for 12 months
43
Placebo + Calcium
This group received a similar supplement without SCF + 600 mg/d of elemental calcium carbonate, administered twice a day Placebo + calcium: Participants consumed a supplement without SCF + calcium carbonate (600 mg/day) for 12 months
46
Total177

Baseline characteristics

CharacteristicTotalSoluble Corn Fiber (SCF) + CalciumSoluble Corn Fiber (SCF) Without CalciumPlaceboPlacebo + Calcium
Age, Continuous12.1 years
STANDARD_DEVIATION 1.51
11.9 years
STANDARD_DEVIATION 1.35
12.1 years
STANDARD_DEVIATION 1.51
12.0 years
STANDARD_DEVIATION 1.23
12.4 years
STANDARD_DEVIATION 1.4
Ethnicity (NIH/OMB)
Hispanic or Latino
128 Participants36 Participants32 Participants33 Participants27 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
49 Participants9 Participants11 Participants10 Participants19 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants0 Participants
Height151.7 cm
STANDARD_DEVIATION 10.4
151.8 cm
STANDARD_DEVIATION 10.8
151.8 cm
STANDARD_DEVIATION 11
149.1 cm
STANDARD_DEVIATION 11.1
154.1 cm
STANDARD_DEVIATION 8.36
Race (NIH/OMB)
American Indian or Alaska Native
5 Participants3 Participants0 Participants1 Participants1 Participants
Race (NIH/OMB)
Asian
6 Participants2 Participants1 Participants1 Participants2 Participants
Race (NIH/OMB)
Black or African American
22 Participants6 Participants3 Participants8 Participants5 Participants
Race (NIH/OMB)
More than one race
7 Participants4 Participants0 Participants0 Participants3 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
57 Participants13 Participants15 Participants18 Participants11 Participants
Race (NIH/OMB)
White
80 Participants17 Participants24 Participants15 Participants24 Participants
Sex: Female, Male
Female
85 Participants25 Participants17 Participants23 Participants20 Participants
Sex: Female, Male
Male
92 Participants20 Participants26 Participants20 Participants26 Participants
Tanner stage2.70 score
STANDARD_DEVIATION 1.23
2.73 score
STANDARD_DEVIATION 1.35
2.57 score
STANDARD_DEVIATION 1.24
2.74 score
STANDARD_DEVIATION 1.23
2.76 score
STANDARD_DEVIATION 1.13
Weight46.3 kg
STANDARD_DEVIATION 11.2
46.8 kg
STANDARD_DEVIATION 11.5
46.7 kg
STANDARD_DEVIATION 10.6
44.6 kg
STANDARD_DEVIATION 12.4
47.1 kg
STANDARD_DEVIATION 10.6

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
0 / 450 / 430 / 430 / 46
other
Total, other adverse events
3 / 451 / 430 / 433 / 46
serious
Total, serious adverse events
0 / 450 / 430 / 430 / 46

Outcome results

Primary

Change in Whole Body Bone Mineral Content (BMC)

Participants underwent a bone scan at baseline and after 12-months in the intervention using a dual energy x-ray absorptiometry (DXA)

Time frame: 12 months

Population: A total of 151 children completed the 12 months visit. Results are presented as change from baseline to the 12 months visit.

ArmMeasureValue (MEAN)Dispersion
Soluble Corn Fiber (SCF) + CalciumChange in Whole Body Bone Mineral Content (BMC)20.1 gramsStandard Deviation 11.8
Soluble Corn Fiber (SCF) Without CalciumChange in Whole Body Bone Mineral Content (BMC)18.6 gramsStandard Deviation 10.5
PlaceboChange in Whole Body Bone Mineral Content (BMC)17.3 gramsStandard Deviation 9.2
Placebo + CalciumChange in Whole Body Bone Mineral Content (BMC)20.7 gramsStandard Deviation 10.6
Comparison: The main analyses were performed on an intention-to-treat basis. For the primary analysis, percent change from baseline in whole-body BMC after one year of supplement (SCF) vs placebo (AIM 1), we used analysis of covariance, adjusted for baseline age, sex, Tanner stage (puberty status), percent change in weight, and percent change in height. Effects were considered significant at the alpha level of 0.05.p-value: 0.37795% CI: [-2.12, 5.53]ANCOVA
Comparison: The main analyses were performed on an intention-to-treat basis. For the secondary analysis, percent change from baseline in whole-body BMC after one year of supplement (SCF+calcium) vs placebo+calcium (AIM 2), we used analysis of covariance, adjusted for baseline age, sex, Tanner stage (puberty status), percent change in weight, and percent change in height. Effects were considered significant at the alpha level of 0.05.p-value: 0.24595% CI: [-1.366, 5.266]ANCOVA
Secondary

Change in Spine BMC

Participants underwent a bone scan at baseline and after 12-months in the intervention using a dual energy x-ray absorptiometry (DXA)

Time frame: 12 months

Population: A total of 151 children completed the 12 months visit, but data from 1 child in the placebo+calcium group for BMC lumbar spine was not included as the DXA machine gave an error and it was not resolved in time and the child did not come back. Results are presented as change from baseline to the 12 months visit.

ArmMeasureValue (MEAN)Dispersion
Soluble Corn Fiber (SCF) + CalciumChange in Spine BMC21.8 gramsStandard Deviation 14.5
Soluble Corn Fiber (SCF) Without CalciumChange in Spine BMC18.7 gramsStandard Deviation 10.8
PlaceboChange in Spine BMC22.4 gramsStandard Deviation 13.2
Placebo + CalciumChange in Spine BMC23.8 gramsStandard Deviation 16.1
Comparison: The main analyses were performed on an intention-to-treat basis. For the secondary analysis, percent change from baseline in lumbar BMC after one year of supplement (SCF) vs placebo, we used analysis of covariance, adjusted for baseline age, sex, Tanner stage (puberty status), percent change in weight, and percent change in height. Effects were considered significant at the alpha level of 0.05.p-value: 0.0595% CI: [-0.765, 8.143]ANCOVA
p-value: 0.0595% CI: [-7.68, 2.435]ANCOVA

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026